Galena Biopharma

Canaccord Genuity acts as Sole Book-Running Manager for US$17 million Public Offering of Common Stock and Warrants for Galena Biopharma

Canaccord Genuity is pleased to announce that on February 13, 2017, it underwrote a public offering of units, consisting of common stock and warrants, for Galena Biopharma. (Nasdaq: GALE). The Company issued a total of 17,000,000 units, each consisting of one share of its common stock and a warrant to purchase one share of its common stock, at a price of US$1.00 per unit. Canaccord Genuity acted as sole book-running manager for the offering.

Galena Biopharma, Inc. is a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs. Galena’s pipeline consists of multiple mid-to-late-stage clinical assets led by its hematology asset, GALE-401, and its novel cancer immunotherapy programs including NeuVax™ (nelipepimut-S) and GALE-301/GALE-302.